What is PathogenDx?
PathogenDx is at the forefront of pathogen detection, offering sophisticated solutions for the cannabis, life sciences, and food industries. Their proprietary D³ Dynamic Dimensional Detection Array technology is designed for rapid and accurate simultaneous detection of multiple pathogens, overcoming the limitations of conventional testing methods. Established in 2014, the company provides a comprehensive suite of testing kits, automation, and software aimed at bolstering health and safety standards across diverse sectors. PathogenDx's commitment to innovation is evident in its partnerships with over 120 laboratories, ensuring robust regulatory compliance and integrity, particularly within the cannabis testing landscape.
How much funding has PathogenDx raised?
PathogenDx has raised a total of $11.7M across 4 funding rounds:
Private Equity
$675K
Series A
$3.4M
Series B
$7.5M
Debt
$150K
Private Equity (2016): $675K, investors not publicly disclosed
Series A (2018): $3.4M led by New Cannabis Ventures
Series B (2019): $7.5M supported by Arcadian Investment Partners, Panther Opportunity Fund, Altitude Investment Management, Cresco Capital Partners, Flatiron Venture Partners, and Salveo Capital
Debt (2020): $150K featuring PPP
Key Investors in PathogenDx
New Cannabis Ventures
New Cannabis Ventures is a premium subscription service providing news and information for cannabis traders and investors, curating content on promising cannabis companies and influential investors since 2013.
Altitude Investment Management
Altitude Investment Management specializes in investing in foundational companies within the emerging global cannabis industry, leveraging extensive experience in alternative asset fund management and investment banking.
Salveo Capital
Salveo Capital focuses on funding the future of the legal cannabis industry by applying institutional discipline to company vetting, investment structures, and portfolio management, aiming to empower entrepreneurs and build sustainable companies.
What's next for PathogenDx?
The recent major strategic investment signals a pivotal moment for PathogenDx, likely enabling accelerated expansion of its technological capabilities and market reach. This capital infusion is expected to fuel further research and development into its advanced pathogen testing solutions, potentially broadening its application across new industries or enhancing its existing offerings for the cannabis, life sciences, and food sectors. The company's trajectory suggests a focus on solidifying its position as a leader in diagnostic technology, with strategic partnerships and market penetration being key priorities moving forward.
See full PathogenDx company page
